Unpicking the combination lock for mutant BRAF and RAS melanomas

Cancer Discovery

Volumn 3, Issue 1, 2013, Pages 13-19

  Al Lazikani, Bissan ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3, 5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO) PYRIDO [2, 3 D] PYRIMIDIN 7 YL] UREA; 1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL] ETHANOL; 2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; 5 (2, 6 DICHLOROBENZYLSULFONYL) 3 [3, 5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1, 3 DIHYDRO 2H INDOL 2 ONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALVESPIMYCIN; B RAF KINASE; BOSUTINIB; DICLOFENAC; DOVITINIB; FLAVOPIRIDOL; LAPATINIB; N [3 (5 CHLORO 1H PYRROLO [2, 3 B] PYRIDINE 3 CARBONYL) 2, 4 DIFLUOROPHENYL] PROPANESULFONAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; OBATOCLAX; RAS PROTEIN; SIMVASTATIN; SUNITINIB; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN;

ARTICLE; CANCER REGRESSION; CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; MELANOMA; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; NOTE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

MLCS; MLOWN;

EID: 84872871751     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0520     Document Type: Article

References (14)

1. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011;470:187-197.
2. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 2012;52:549-573.
3. Gatenby R. Finding cancer's first principles. Nature 2012;491:S55.
4. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-692.
5. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, et al. Genotype-selective combination therapies for melanoma identifi ed by high-throughput drug screening. Cancer Discov 2013;3:52-67.
6. Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012;2:214-226.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
8. Kudchadkar R, Paraiso KH, Smalley KS. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 2012;18:124-131.
9. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010;107:14903-14908.
10. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;151:209-221.
11. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-103.
12. Roller DG, Axelrod M, Capaldo BJ, Jensen K, Mackay A, Weber M Y, et al. Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther 2012;11:2505-2515.
13. Bernards R. A missing link in genotype-directed cancer therapy. Cell 2012;151:465-468.
14. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani A. Analysis: Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 2013;12:35-50.